Skip to content
2000
Volume 4, Issue 5
  • ISSN: 1567-2050
  • E-ISSN: 1875-5828

Abstract

The receptor for advanced glycation end products (RAGE) binds amyloid peptides with high affinity. Soluble RAGE-like peptides and Aβ-like peptides occur in relatively high concentrations in the circulation of individuals with Alzheimer's disease. Protein complexes with epitopes for both Aβ and RAGE are also present. At physiological concentrations, forms of Aβ have different, but relatively low potencies as cytotoxicants in neural cells in culture. The purpose of this study was to determine whether a synthetic peptide complex composed of Aβ1-42 and RAGE23-54, a conserved Nterminal fragment of RAGE, exhibited increased cytotoxicity in comparison with the constituent peptides. Western analysis indicated that Aβ1-42 and RAGE23-54 remained primarily in their original low molecular weight states (4-6 kDa) during the maintenance of the individual peptides (37 ° C) in water from 1 to 4 weeks. In contrast, over the same maintenance periods the combined Aβ1-42 and RAGE23-54 peptides shifted to higher molecular weight complexes (up to 80-120 kDa). Protein complexes of similar molecular weights with epitopes for Aβ and RAGE antibodies were identified in human plasma. Incubation of differentiated PC-12 cells with 10-100 μM Aβ1-42 or with RAGE23-54 resulted in concentration-dependent decreases in cell viability. The cytotoxicity of each peptide was slightly enhanced by the progressive maintenance of Aβ1- 42 and RAGE23-54 in water over 3 weeks prior to the assay. Under the same conditions, the Aβ1-42 - RAGE23-54 complex became significantly more cytotoxic. These results suggest that the formation of soluble Aβ-RAGE complexes in Alzheimer's disease could represent a mechanism for enhancing the neurotoxicity of amyloid peptides.

Loading

Article metrics loading...

/content/journals/car/10.2174/156720507783018325
2007-12-01
2025-04-22
Loading full text...

Full text loading...

/content/journals/car/10.2174/156720507783018325
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test